Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more U.K. authorities banned ads for weight loss services because they promoted prescription drugs ...

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound By Ashley Capoot, CNBC and Annika Kim Constantino, CNBC • Published July 16, 2025 • Updated on July ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s nonprofit acquires 23andMe.